Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Amid rising cancer incidence in the Asia Pacific region, Roche tells Scrip in this exclusive interview that it is going "beyond the pill" to widen access to drugs in the increasingly important oncology market.
After a long-standing row with payer NHS England, the rapid market access deal will help Vertex move into growth phase.
G1 Therapeutics had been talking about marketing its recently filed myelosuppression therapy for small cell lung cancer on its own. However a deal with Boehringer represents an alternative "capital efficient launch structure."
The Stockholm-headquartered company has exceeded expectations with its IPO, and now faces the ‘big reveal’ for its lead asset Nefecon.
The Swiss major is offering a ‘Day One’ access program to governments and reimbursement agencies for Zolgensma, which is already available in France and will be shortly in Germany.
Qinlock (ripretinib), approved as the US FDA rejected Blueprint Medicines’ Ayvakit (avapritinib) in the same indication, is priced on par with the rival drug cleared in January for a narrower GIST use.
AstraZeneca's biopharmaceuticals president Ruud Dobber tells Scrip that the price for Farxiga in the heart failure indication should reflect its potential to improve survival and reduce the need for hospitalization.
The acquisition brings Alexion the bleeding reversal agent Andexxa, which execs called a synergistic addition to its portfolio – but analysts are struggling to see the match with Alexion’s chronic rare disease therapies.
GlaxoSmithKline expects regulatory approval for three key cancer products by the middle of this year, anchoring it as a leading oncology company, Axel Hoos tells Scrip.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.